Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Down Syndrome 2Lymphoma, Extranodal NK-T-Cell 1Leukemia, Biphenotypic, Acute 1

Interventions

sugemalimab 1pegaspargase 1fludarabine phosphate 1Whole-Body Irradiation 1Tacrolimus 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Oxaliplatin 1Mycophenolic Acid 1Methotrexate 1Melphalan 1Gemcitabine 1Etoposide 1Cyclosporine 1Cyclophosphamide 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Extranodal NK-T-Cell × pegaspargase × 30 days × Clear all
NCT05700448 2026-05-27

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

CStone Pharmaceuticals

Phase 3 Not yet recruiting
150 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡